Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > The presentations at ADC event

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Oct 15, 2023 10:33pm

102 Views

Post# 35684703

RE:RE:RE:The presentations at ADC event

https://storage.pardot.com/448062/1697028037jVdgNYsT/14th_World_ADC_San_Diego___Event_Guide_FINAL.pdf

Mannequin wrote:
the link doesn't work so you have one?

scarlet1967 wrote:

October 16:

"Improving the Therapeutic Window of Anti-Cancer Therapeutics:

Exploiting the Scavenger Property of the Sortilin

(SORT1) Receptor to Enable Targeted Delivery of Peptide

Drug Conjugates (PDC's)

• Reviewing the rationale for targeting the SORT1 receptor in cancer

• Facilitating rapid delivery of anticancer agents using PDC technology

• Discussing additional effects on the tumor micro environment (ME)

• Outlining potential combinations with many anti-cancer agents"

October 18:

"Sudoxetaxel zendusortide

(TH1902):A Novel Peptide Drug Conjugate's Journey From the Preclinical to the Clinical Setting

• Understanding the potential utility of Sortilin as a biomarker for cancer

• Introducing Sudocetaxel zendusortide as a promising therapy for metastatic cancer with a unique mechanism of action that involves rapid internalization into cancer cells through the Sortilin receptor

• Reviewing the ongoing Phase I FIH study investigating Sudocetaxel zendusortide, including its study design, dosing, safety, and early signs of efficacy"